People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.

NCT Number	NCT07207148
Lead Sponsor	Northwestern University Collaborators: Genentech, Inc.
Conditions	Multiple Sclerosis
Enrollment	100 participants
Start Date	2025-11-15
Primary Completion	2028-04-01 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-17